• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

检测南美人源和动物源肺炎克雷伯菌复合体中 KPC-2 和 NDM-1 的共表达。

Detecting KPC-2 and NDM-1 Coexpression in Klebsiella pneumoniae Complex from Human and Animal Hosts in South America.

机构信息

Department of Microbiology, Institute of Biomedical Sciences, Universidade de São Paulo, São Paulo, Brazil.

Department of Clinical Analysis, School of Pharmacy, Universidade de São Paulo, São Paulo, Brazil.

出版信息

Microbiol Spectr. 2022 Oct 26;10(5):e0115922. doi: 10.1128/spectrum.01159-22. Epub 2022 Aug 18.

DOI:10.1128/spectrum.01159-22
PMID:35980188
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9604071/
Abstract

Reports of Gram-negative bacteria harboring multiple carbapenemase genes have increased in South America, leading to an urgent need for appropriate microbiological diagnosis. We evaluated phenotypic methods for detecting Klebsiella pneumoniae carbapenemase 2 (KPC-2) and New Delhi metallo-β-lactamase-1 (NDM-1) coexpression in members of the K. pneumoniae complex (i.e., K. pneumoniae, K. quasipneumoniae, and K. variicola) isolated from human and animal hosts, based on inhibition of ceftazidime-avibactam (CZA) and aztreonam (ATM) by dipicolinic acid (DPA), EDTA, or avibactam (AVI). While the presence of and genes was confirmed by whole-genome sequencing, PCR, and/or GeneXpert, coexpression was successfully detected based on the following: (i) a ≥5-mm increase in the zone diameter of ATM (30 µg) disks plus AVI (4 or 20 µg) and ≥4-mm and ≥10-mm increases in the zone diameters for "CZA 50" (30 µg ceftazidime [CAZ] and 20 µg AVI) and "CZA 14" (10 µg CAZ and 4 µg AVI) disks, respectively, when we added DPA (1 mg/disk) or EDTA (5 mM) in a combined disk test (CDT); (ii) a positive ghost zone (synergism) between ATM (30 µg) and CZA 50 disks and between CZA 50 and DPA (1 mg) disks, using the double-disk synergy test (DDST) at a disk-disk distance of 2.5 cm; (iii) ≥3-fold MIC reductions of ATM and CZA in the presence of AVI (4 µg/mL), DPA (500 µg/mL), or EDTA (320 µg/mL); and (iv) immunochromatography. Although our results demonstrated that inhibition by AVI, DPA, and EDTA may provide simple and inexpensive methods for the presumptive detection of coexpression of KPC-2 and NDM-1 in members of the K. pneumoniae complex, additional studies are necessary to confirm the accuracy of these methodologies by testing other Gram-negative bacterial species and other KPC and NDM variants coexpressed by WHO critical priority pathogens detected worldwide. Alerts regarding the emergence and increase of combinations of carbapenemases in in Latin America and the Caribbean have recently been issued by PAHO and WHO, emphasizing the importance of appropriate microbiological diagnosis and the effective and articulated implementation of infection prevention and control programs. In this study, we evaluated methods based on inhibition of ceftazidime (CAZ), ceftazidime-avibactam (CZA), and aztreonam (ATM) by dipicolinic acid (DPA), EDTA, and avibactam (AVI) inhibitors for the identification of KPC-2- and NDM-1-coexpression in members of the K. pneumoniae complex recovered from human and animal hosts. Our results demonstrate that inhibition by AVI, DPA, and EDTA may provide simple and inexpensive methods for the presumptive detection of coexpression of KPC-2 and NDM-1 in members of the K. pneumoniae complex.

摘要

关于南美洲携带多种碳青霉烯酶基因的革兰氏阴性菌的报告有所增加,这导致对适当的微生物学诊断产生了迫切需求。我们评估了表型方法,用于检测从人类和动物宿主中分离的肺炎克雷伯菌复合体(即肺炎克雷伯菌、肺炎克雷伯菌和肺炎克雷伯菌)中同时表达的肺炎克雷伯菌碳青霉烯酶 2(KPC-2)和新德里金属β-内酰胺酶-1(NDM-1),基于抑制头孢他啶-阿维巴坦(CZA)和氨曲南(ATM)由二吡啶酸(DPA)、EDTA 或阿维巴坦(AVI)。虽然通过全基因组测序、PCR 和/或 GeneXpert 证实了 和 基因的存在,但通过以下方法成功检测到了共表达:(i)ATM(30 µg)纸片加 AVI(4 或 20 µg)的环直径增加≥5 mm,并且“CZA 50”(30 µg 头孢他啶[CAZ]和 20 µg AVI)和“CZA 14”(10 µg CAZ 和 4 µg AVI)纸片的环直径分别增加≥4 和≥10 mm,当我们在联合纸片试验(CDT)中添加 DPA(1 mg/disk)或 EDTA(5 mM)时;(ii)在 ATM(30 µg)和 CZA 50 磁盘之间以及 CZA 50 和 DPA(1 mg)磁盘之间存在阳性幽灵区(协同作用),使用双磁盘协同试验(DDST)在磁盘-磁盘距离为 2.5 cm 时;(iii)当存在 AVI(4 µg/mL)、DPA(500 µg/mL)或 EDTA(320 µg/mL)时,ATM 和 CZA 的 MIC 降低了 3 倍以上;和(iv)免疫层析。尽管我们的结果表明,AVI、DPA 和 EDTA 的抑制作用可能为同时检测肺炎克雷伯菌复合体中 KPC-2 和 NDM-1 的共表达提供简单且廉价的方法,但需要进行更多研究,以通过测试其他革兰氏阴性细菌物种和其他在全球检测到的世界卫生组织关键优先病原体表达的 KPC 和 NDM 变体来确认这些方法的准确性。最近,泛美卫生组织和世界卫生组织发布了关于在拉丁美洲和加勒比地区出现和增加碳青霉烯酶组合的警报,强调了适当的微生物学诊断以及有效和协调的感染预防和控制计划实施的重要性。在这项研究中,我们评估了基于头孢他啶(CAZ)、头孢他啶-阿维巴坦(CZA)和氨曲南(ATM)抑制作用的方法,通过二吡啶酸(DPA)、EDTA 和阿维巴坦(AVI)抑制剂来鉴定从人类和动物宿主中分离的肺炎克雷伯菌复合体中 KPC-2 和 NDM-1 的共表达。我们的结果表明,AVI、DPA 和 EDTA 的抑制作用可能为同时检测肺炎克雷伯菌复合体中 KPC-2 和 NDM-1 的共表达提供简单且廉价的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfad/9604071/2419862761ef/spectrum.01159-22-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfad/9604071/885608de8d55/spectrum.01159-22-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfad/9604071/2419862761ef/spectrum.01159-22-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfad/9604071/885608de8d55/spectrum.01159-22-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfad/9604071/2419862761ef/spectrum.01159-22-f002.jpg

相似文献

1
Detecting KPC-2 and NDM-1 Coexpression in Klebsiella pneumoniae Complex from Human and Animal Hosts in South America.检测南美人源和动物源肺炎克雷伯菌复合体中 KPC-2 和 NDM-1 的共表达。
Microbiol Spectr. 2022 Oct 26;10(5):e0115922. doi: 10.1128/spectrum.01159-22. Epub 2022 Aug 18.
2
A simple disk pre-diffusion test to predict in vitro aztreonam/avibactam activity against NDM-producing Klebsiella pneumoniae complex.一种简单的磁盘预扩散试验,用于预测产 NDM 肺炎克雷伯菌复合体对阿兹台农/阿维巴坦的体外活性。
J Glob Antimicrob Resist. 2022 Mar;28:49-52. doi: 10.1016/j.jgar.2021.12.009. Epub 2021 Dec 20.
3
Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection.头孢他啶-阿维巴坦治疗对 ST307 型肺炎克雷伯菌高危克隆中新出现的 KPC 变异体的影响及其对其常规检测的后果。
J Clin Microbiol. 2022 Mar 16;60(3):e0224521. doi: 10.1128/jcm.02245-21.
4
Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.中国耐碳青霉烯类肺炎克雷伯菌中头孢他啶/阿维巴坦耐药的出现。
Clin Microbiol Infect. 2020 Jan;26(1):124.e1-124.e4. doi: 10.1016/j.cmi.2019.08.020. Epub 2019 Sep 5.
5
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .头孢他啶-阿维巴坦对产碳青霉烯酶的. 的体外和体内杀菌活性。
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
6
Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant .头孢他啶-阿维巴坦联合不同抗菌药物对碳青霉烯类耐药. 的影响。
Microbiol Spectr. 2024 Jun 4;12(6):e0010724. doi: 10.1128/spectrum.00107-24. Epub 2024 May 7.
7
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?头孢他啶-阿维巴坦和氨曲南能否克服肠杆菌科细菌中金属β-内酰胺酶介导的β-内酰胺耐药性?
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02243-16. Print 2017 Apr.
8
Reversion of KPC-114 to KPC-2 in ceftazidime-avibactam- resistant/meropenem-susceptible ST11 is related to low mutation rates.产碳青霉烯酶肺炎克雷伯菌 ST11 对头孢他啶-阿维巴坦耐药/美罗培南敏感的 KPC-114 向 KPC-2 的回复与低突变率有关。
Microbiol Spectr. 2024 Oct 3;12(10):e0117324. doi: 10.1128/spectrum.01173-24. Epub 2024 Aug 27.
9
Acquisition of a Stable and Transferable -Positive Plasmid With Low Fitness Cost Leading to Ceftazidime/Avibactam Resistance in KPC-2-Producing During Treatment.在治疗过程中,携带低适应性成本的稳定且可转移的头孢他啶/阿维巴坦耐药阳性质粒导致 KPC-2 产酶株获得耐药性。
Front Cell Infect Microbiol. 2021 Jul 20;11:658070. doi: 10.3389/fcimb.2021.658070. eCollection 2021.
10
Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae.头孢他啶-阿维巴坦联合用药治疗产碳青霉烯酶肺炎克雷伯菌(KPC)导致实验性骨髓炎的疗效。
Int J Antimicrob Agents. 2023 Jan;61(1):106702. doi: 10.1016/j.ijantimicag.2022.106702. Epub 2022 Dec 5.

引用本文的文献

1
Resistance of Gram-Negative Bacteria to Cefepime-Enmetazobactam: A Systematic Review.革兰氏阴性菌对头孢吡肟-恩美他唑巴坦的耐药性:一项系统评价
Pathogens. 2025 Aug 6;14(8):777. doi: 10.3390/pathogens14080777.
2
Outbreak of NDM-5-producing in intensive care units: an overlooked pathogen in Argentina?重症监护病房中产NDM-5细菌的暴发:阿根廷一种被忽视的病原体?
Microbiol Spectr. 2025 Aug 5;13(8):e0067225. doi: 10.1128/spectrum.00672-25. Epub 2025 Jun 23.
3
Phenotypic and Molecular Characterization of Extended-Spectrum β-Lactamase, Plasmid-Mediated- AmpC, and Carbapenemase-Producing Enterobacteriaceae Isolated from Companion and Production Animals in Brazil.

本文引用的文献

1
Emergence of a Hypervirulent Tigecycline-Resistant Strain Co-producing and With an Uncommon Sequence Type ST464 in Southwestern China.中国西南部出现一株高毒力、耐替加环素且共产生物被膜的菌株,其序列型为罕见的ST464 。
Front Microbiol. 2022 Apr 29;13:868705. doi: 10.3389/fmicb.2022.868705. eCollection 2022.
2
Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant : A Multi-Center Study in Southwest China.氨曲南/阿维巴坦和头孢他啶/阿维巴坦对耐碳青霉烯类细菌的遗传多样性及体外活性:中国西南地区的多中心研究
Infect Drug Resist. 2022 Apr 27;15:2243-2251. doi: 10.2147/IDR.S357396. eCollection 2022.
3
从巴西伴侣动物和生产动物中分离出的产超广谱β-内酰胺酶、质粒介导的AmpC酶和碳青霉烯酶肠杆菌科细菌的表型及分子特征
Curr Microbiol. 2025 Feb 4;82(3):112. doi: 10.1007/s00284-025-04104-5.
4
Blood-rsCDM: a new rapid and simplified carbapenemase detection method for detecting carbapenemases in Enterobacterales directly from positive blood cultures.血 rsCDM:一种新的快速简化的碳青霉烯酶检测方法,可直接从阳性血培养物中检测肠杆菌科的碳青霉烯酶。
BMC Microbiol. 2024 Oct 16;24(1):410. doi: 10.1186/s12866-024-03553-5.
5
Performance of Flow Cytometry-Based Rapid Assay in Detection of Carbapenemase-Producing Enterobacterales.基于流式细胞术的快速检测在产碳青霉烯酶肠杆菌科中的应用性能。
Int J Mol Sci. 2024 Jul 18;25(14):7888. doi: 10.3390/ijms25147888.
6
Prevalence of ST1049-KL5 carbapenem-resistant Klebsiella pneumoniae with a bla and bla co-carrying hypertransmissible IncM1 plasmid.ST1049-KL5 碳青霉烯类耐药肺炎克雷伯菌的流行,其携带 bla 和 bla 共同携带的超可传播 IncM1 质粒。
Commun Biol. 2024 Jun 6;7(1):695. doi: 10.1038/s42003-024-06398-w.
7
In-depth characterization of multidrug-resistant NDM-1 and KPC-3 co-producing bloodstream isolates from Italian hospital patients.深入分析来自意大利医院患者的产 NDM-1 和 KPC-3 型多药耐药菌血流分离株。
Microbiol Spectr. 2024 Apr 2;12(4):e0330523. doi: 10.1128/spectrum.03305-23. Epub 2024 Feb 27.
8
Molecular characterization of carbapenemase-producing Enterobacterales in a tertiary hospital in Lima, Peru.秘鲁利马一家三级医院产碳青霉烯酶肠杆菌科的分子特征。
Microbiol Spectr. 2024 Feb 6;12(2):e0250323. doi: 10.1128/spectrum.02503-23. Epub 2024 Jan 9.
9
Characterisation of a Novel Hybrid IncFII:IncR:IncN Plasmid Co-Harboring and from a Clinical ST11 Carbapenem-Resistant Strain.一株临床ST11碳青霉烯耐药菌株中携带的新型IncFII:IncR:IncN杂交质粒的特性分析
Infect Drug Resist. 2023 Dec 12;16:7621-7628. doi: 10.2147/IDR.S435195. eCollection 2023.
10
Emergence of KPC-113 and KPC-114 variants in ceftazidime-avibactam-resistant belonging to high-risk clones ST11 and ST16 in South America.在南美洲,属于高风险克隆株ST11和ST16的对头孢他啶-阿维巴坦耐药菌株中出现了KPC-113和KPC-114变体。
Microbiol Spectr. 2023 Sep 6;11(5):e0037423. doi: 10.1128/spectrum.00374-23.
Genomic characterization of a carbapenem-resistant Citrobacter freundii cocarrying bla and bla.
碳青霉烯类耐药弗氏柠檬酸杆菌同时携带 bla 和 bla 的基因组特征分析
J Glob Antimicrob Resist. 2022 Jun;29:289-292. doi: 10.1016/j.jgar.2022.04.014. Epub 2022 Apr 27.
4
[Evaluation of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem, and Colistin Single and Binary Combinations Against Carbapenem Resistant Klebsiella pneumoniae Strains Isolated from Various Clinical Specimens].[头孢他啶-阿维巴坦、美罗培南和黏菌素单药及二元组合对从各种临床标本中分离出的耐碳青霉烯类肺炎克雷伯菌菌株的体外疗效评估]
Mikrobiyol Bul. 2022 Apr;56(2):230-250. doi: 10.5578/mb.20229804.
5
Coexistence of two bla genes in a bla-carrying multidrug-resistant ST15 Klebsiella pneumoniae isolate recovered from cerebrospinal fluid in China.在中国从脑脊液中分离出的一株 bla 基因携带的多药耐药 ST15 型肺炎克雷伯菌中存在两种 bla 基因。
J Glob Antimicrob Resist. 2022 Jun;29:232-235. doi: 10.1016/j.jgar.2022.04.006. Epub 2022 Apr 14.
6
Meropenem/Vaborbactam Plus Aztreonam as a Possible Treatment Strategy for Bloodstream Infections Caused by Ceftazidime/Avibactam-Resistant : A Retrospective Case Series and Literature Review.美罗培南/巴硼巴坦联合氨曲南作为治疗头孢他啶/阿维巴坦耐药引起的血流感染的一种可能治疗策略:一项回顾性病例系列研究及文献综述
Antibiotics (Basel). 2022 Mar 10;11(3):373. doi: 10.3390/antibiotics11030373.
7
A practical laboratory method to determine ceftazidime-avibactam-aztreonam synergy in patients with New Delhi metallo-beta-lactamase (NDM)-producing Enterobacterales infection.一种实用的实验室方法,用于确定产新德里金属β-内酰胺酶(NDM)肠杆菌科感染患者中头孢他啶-阿维巴坦-氨曲南的协同作用。
J Glob Antimicrob Resist. 2022 Jun;29:558-562. doi: 10.1016/j.jgar.2022.01.025. Epub 2022 Feb 4.
8
Comparative Evaluation of Phenotypic Synergy Tests versus RESIST-4 O.K.N.V. and NG Test Carba 5 Lateral Flow Immunoassays for the Detection and Differentiation of Carbapenemases in and Pseudomonas aeruginosa.对表型协同试验与 RESIST-4 O.K.N.V. 和 NG 测试 CarbA 5 侧向流免疫测定法用于检测和区分 肠杆菌科细菌和铜绿假单胞菌中产碳青霉烯酶的比较评估。
Microbiol Spectr. 2022 Feb 23;10(1):e0108021. doi: 10.1128/spectrum.01080-21. Epub 2022 Feb 2.
9
Environmental spreading of clinically relevant carbapenem-resistant gram-negative bacilli: the occurrence of bla strains relates to local hospital activities.临床相关碳青霉烯类耐药革兰氏阴性杆菌的环境传播:bla 菌株的出现与当地医院活动有关。
BMC Microbiol. 2022 Jan 4;22(1):6. doi: 10.1186/s12866-021-02400-1.
10
A simple disk pre-diffusion test to predict in vitro aztreonam/avibactam activity against NDM-producing Klebsiella pneumoniae complex.一种简单的磁盘预扩散试验,用于预测产 NDM 肺炎克雷伯菌复合体对阿兹台农/阿维巴坦的体外活性。
J Glob Antimicrob Resist. 2022 Mar;28:49-52. doi: 10.1016/j.jgar.2021.12.009. Epub 2021 Dec 20.